Lutetium (177Lu) chloride

Lutetium (177Lu) chloride
Clinical data
Trade namesLumark, EndolucinBeta, Illuzyce
AHFS/Drugs.comLumark UK Drug Information
EndolucinBeta UK Drug Information
Pregnancy
category
ATC code
  • None
Legal status
Legal status
Identifiers
  • (177Lu)lutetium(3+) trichloride
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaCl3Lu
Molar mass281.32 g·mol−1
3D model (JSmol)
  • [Cl-].[Cl-].[Cl-].[177Lu+3]
  • InChI=1S/3ClH.Lu/h3*1H;/q;;;+3/p-3/i;;;1+2
  • Key:AEDROEGYZIARPU-SUNKFXMWSA-K

Lutetium (177Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy (medical imaging).[5][6] It is an isotopomer of lutetium(III) chloride containing the radioactive isotope 177Lu, which undergoes beta decay with a half-life of 6.64 days.[8]

  1. ^ a b "Lutetium (177Lu) Chloride APMDS". Therapeutic Goods Administration (TGA). 21 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  2. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
  3. ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  4. ^ "ANSTO Lutetium (177Lu) Chloride Radiochemical Solution for injection vial". Archived from the original (PDF) on 30 July 2022.
  5. ^ a b "Lumark EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 7 May 2020. Text was copied from this source under the copyright of the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ^ a b "EndolucinBeta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 October 2020. Retrieved 7 May 2020. Text was copied from this source under the copyright of the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ "Illuzyce EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ Ladrière T, Faudemer J, Levigoureux E, Peyronnet D, Desmonts C, Vigne J (April 2023). "Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals". Pharmaceutics. 15 (4): 1240. doi:10.3390/pharmaceutics15041240. PMC 10145759. PMID 37111725.